Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on April 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Dr. Erlander resigned from Cardiff Oncology’s board on March 27, 2026.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Dr. Erlander resigned from Cardiff Oncology’s board on March 27, 2026
- Filing contains no material agreement terms despite Item 1.01 classification
- Board departure may affect governance and clinical-strategy oversight
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.